不同治疗方案对H22肝癌荷瘤小鼠的疗效比较  

Comparison of the curative effect of three therapeutic regimens on H22 hepatoma-bearing mice

作　　者：张园园[1] 方肇勤[1] 王艳明[1] 

机构地区：[1]上海中医药大学基础医学院,上海201203

出　　处：《中国实验动物学报》2014年第3期67-71,77,共6页Acta Laboratorium Animalis Scientia Sinica

基　　金：国家科技重大专项课题(课题编号:2009ZX09502-018)

摘　　要：目的比较不同治疗方案对H22肝癌荷瘤小鼠的疗效。方法采用H22腋下实体瘤KM小鼠及小鼠标准化、计量化辨证方法,观察复合化疗方案局部注射、索拉非尼口服,及两者联合应用等对小鼠抑瘤率和证候的影响。结果所选用3个治疗方案均具有一定的抑瘤作用,综合对气血阴阳证候的影响及胸腺和脾脏重量,以复合化疗方案局部注射联合索拉非尼口服最好。结论局部介入联合索拉非尼口服方案疗效较好。Objective To compare the therapeutic effect of three treatment regimens on H 22 tumor-bearing mice. Methods H22 tumor-bearing mice were treated by local injection of compound chemotherapeutic agents （5-FU, mitomy-cin and cisplatin ） , oral administration of sorafeni , or the both combined , respectively .Standardized and quantitative syn-drome differentiation methods were used to assess the syndromes and tumor-inhibition rate in the mice .Results All these three therapeutic regimens were effective in suppressing the tumor growth in mice .Among them, the combined therapeutic regimen of local injection of compound chemotherapeutic drugs plus oral administration of sorafeni was the best .Conclusion The effect of sorafenib combined with local injection of compound chemotherapeutic agents is better than the other two regimens used separately .

关 键 词：肝癌 小鼠 治疗方案 疗效 

分 类 号：Q95-33[生物学—动物学] R394.2[医药卫生—医学遗传学]